Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Operating Grant - PA: Cancer Research (bridge funding)

Université Laval

$100,000.00

FXR: a promising target for prostate cancer treatment

EF 2008-09

Résumé
Prostate cancer is the most frequently diagnosed malignancy in Canadian males and the third leading cause of cancer-related death in men in most Western industrialized countries. Estimations assume that approximately 660,000 men worldwide will be diagnosed with this form of cancer and 250,000 men will die from it in 2010. We discovered that a series of natural or synthetic compounds, which modulate gene expression through activation of a protein named FXR, are efficient blockers of the growth of common prostate cancer cell lines. In this application, we propose to determine the therapeutic interest of these molecules in vitro and in animals models.
Programme
Operating Grant - PA: Cancer Research (bridge funding)
Bénéficiaire
Emplacement
Quebec, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
177853
Name
Barbier Olivier
Region
Québec
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Cancer Research
Theme2
Biomedical
Prcname2
Pharmacology & Toxicology
Projecttitle
FXR: a promising target for prostate cancer treatment
Programtype2
Operating Grants
Orgnameinp2
Université Laval
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Operating Grant - PA: Cancer Research (bridge funding)
Keyworddelim
Apoptosis; Cell Cycle; Fxr; Prostate Cancer; Urso; Xenograft
Abstract
Prostate cancer is the most frequently diagnosed malignancy in Canadian males and the third leading cause of cancer-related death in men in most Western industrialized countries. Estimations assume that approximately 660,000 men worldwide will be diagnosed with this form of cancer and 250,000 men will die from it in 2010. We discovered that a series of natural or synthetic compounds, which modulate gene expression through activation of a protein named FXR, are efficient blockers of the growth of common prostate cancer cell lines. In this application, we propose to determine the therapeutic interest of these molecules in vitro and in animals models.
Competitiondate
200809
Approvedterm2
1 yr 0 mth
Pinamesdelim
Barbier, Olivier
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~